
DBD Stock Forecast & Price Target
DBD Analyst Ratings
Bulls say
Diebold Nixdorf is expected to experience strong financial performance in the future, thanks to robust demand for their products in key markets and strategic operational improvements. With a solid balance sheet and plans for increased buybacks, there is potential for a re-rating and attractive free cash flow yields. Despite some risks, analysts are optimistic about the company's prospects and have raised their price target to $100, with a projected EPS of $80 for 2027.
Bears say
Diebold Nixdorf is benefiting from their domestic factory and lean practices leading to significant growth potential and partnerships with major retailers in both general merchandise and grocery segments. Additionally, their undemanding valuation, lower leverage compared to its closest peer, and consistent FCF generation through share buybacks indicate a positive outlook. Lastly, potential tailwinds from lower operating expenses, declining tax rates, and possibly lower interest expenses further support a positive outlook for the company.
This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.
DBD Analyst Forecast & Price Prediction
Start investing in DBD
Order type
Buy in
Order amount
Est. shares
0 shares